MECP2 and Rett syndrome: Taken together, our results suggest that the genetic background underlying the MECP2 mutation is strongly associated with OS in classical RTT patients and may contribute to a better understanding of the biological mechanisms for the observed benefits of PUFA supplementation in classical RTT patients.